• Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases
• Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end

Carlsbad, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the launch of its new corporate branding and website, palisadebio.com and reiterated its commitment to stakeholders by advancing its lead product candidate, PALI-2108.

“We remain committed to our mission of developing differentiated product candidates for immune, inflammatory and fibrotic diseases in established commercial markets where there is a significant unmet medical need. As we continue to advance our pipeline programs, enhance our growing body of data, and build momentum toward value-driving milestones, we believed it was essential to align our corporate brand to clearly reflect the overarching vision we have for Palisade Bio,” commented J.D. Finley, Chief Executive Officer of Palisade. “We believe that next-generation precision therapies will be vital in targeting these diseases, and our focus is on advancing our programs to be able to help the millions of patients living with them every day. The data we have collected to-date continues to reinforce our confidence as we advance toward several key clinical and regulatory milestones. I am excited for this next phase of evolution and the opportunity to unlock the full potential value of Palisade Bio.”

The Company’s lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis poses significant challenges for patients who need therapies that provide effective remission rates, that are non-immunosuppressive and that have improved safety profiles. Once clinical trials begin, the Company anticipates using advanced machine learning to identify patients with elevated PDE4 activity to enhance the responder population using PALI-2108 to target ulcerative colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, the Company will be able to identify top PDE4-effector genes, potentially enabling Palisade to predict patient responses to PDE4 inhibitors and hopefully ensure targeted, effective treatment.

Additionally, the Company’s platform technology provides the opportunity to expand its pipeline across immune, inflammatory and fibrotic disease, including its PALI-1908 program in preclinical development for fibro stenotic Crohn’s Disease, which shares multiple synergies with the lead PALI-2108 program.

In addition to the launch of its new website, the Company has released its latest corporate presentation, now available in the Investors section of the Company’s website. For more information and to stay updated, please visit the company's website (palisadebio.com) and connect on X, Facebook, and LinkedIn.

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Forward Looking Statements

This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s most recent Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on March 26, 2024 and August 12, 2024, respectively. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
833-475-8247
This email address is being protected from spambots. You need JavaScript enabled to view it.